Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

142
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
142
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

147
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
147
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.

United European gastroenterology journal·2026
Same author

GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.

Therapeutic advances in gastroenterology·2026
Same author

Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort Study.

Medicina (Kaunas, Lithuania)·2025
Same author

Plasma protein glycosylation: a biomarker for predicting metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.

Revista espanola de enfermedades digestivas·2025
Same author

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases.

International journal of molecular sciences·2025
Same author

Assessing inflammatory bowel disease monitoring procedures in Spain: insights from the IBD-PODCAST study.

Revista espanola de enfermedades digestivas·2025

Related Experiment Video

Updated: Jul 5, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management.

P Vega1, J M Huguet2, E Gómez3

  • 1Complejo Hospitalario Universitario de Ourense, Orense, Spain.

Digestive Diseases and Sciences
|January 13, 2024
PubMed
Summary

Many inflammatory bowel disease (IBD) patients have suboptimal disease control, leading to reduced quality of life and increased healthcare costs. Better treatment strategies are needed for Crohn's disease (CD) and ulcerative colitis (UC) patients.

Keywords:
Crohn’s diseaseInflammatory bowel diseasesSTRIDE II recommendationsTreat to target strategyUlcerative colitis

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

125

Related Experiment Videos

Last Updated: Jul 5, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.4K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

125

Area of Science:

  • Gastroenterology and Hepatology
  • Clinical Research
  • Inflammatory Bowel Disease (IBD) Studies

Background:

  • Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), can cause irreversible bowel damage and significant long-term complications.
  • Suboptimal control of IBD is linked to increased healthcare resource utilization (HCRU), diminished quality of life (QoL), and reduced work productivity.

Purpose of the Study:

  • To assess the proportion of IBD patients experiencing suboptimal disease control.
  • To evaluate the impact of suboptimal IBD control on patients' QoL, HCRU, and work productivity.

Main Methods:

  • The IBD-PODCAST study employed a cross-sectional, multicenter design.
  • Characterized CD and UC patients based on optimal or suboptimal control using STRIDE-II criteria and patient/physician-reported measures.
  • Results presented are from the Spanish cohort comprising 396 patients.

Main Results:

  • Over half of CD patients (53.1%) and 41.5% of UC patients exhibited suboptimal disease control.
  • Despite high rates of targeted immunomodulator use (72.7% in CD, 40.9% in UC), suboptimal control persisted.
  • Suboptimally controlled IBD patients reported impaired QoL, higher HCRU, increased direct costs, and lost work productivity compared to optimally controlled patients.

Conclusions:

  • A significant percentage of IBD patients, even those on targeted immunomodulators, demonstrate suboptimal disease control per STRIDE II criteria.
  • Suboptimal control is associated with substantial negative impacts on QoL, work productivity, and HCRU.
  • There is a clear need for improved therapeutic approaches to enhance disease control in IBD management.